X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
RVU120 is a selective, first-in-class dual CDK8/CDK19 kinase inhibitor that has shown signs of clinical activity in treated patients, as well as efficacy in numerous in vitro and in vivo models of hematologic malignancies and solid tumors.
Lead Product(s): RVU120
Therapeutic Area: Oncology Product Name: RVU120
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ryvu Therapeutics
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Agreement July 06, 2023
Details:
RVU120 is a selective, first-in-class dual CDK8/19 kinase inhibitor. It is being developed for the treatment of patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Lead Product(s): RVU120
Therapeutic Area: Oncology Product Name: RVU120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
RVU120 is a selective, first-in-class dual CDK8/19 kinase inhibitor. It is being evaluated in phase 2 clinical trials in combination with venetoclax for the treatment of patients with relapsed/refractory AML.
Lead Product(s): RVU120,Venetoclax
Therapeutic Area: Oncology Product Name: RVU120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2024
Details:
RVU120 is a selective CDK8/CDK19 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors currently in phase I clinical development for the treatment of acute myeloid leukemia and myelodysplastic syndromes.
Lead Product(s): RVU120
Therapeutic Area: Oncology Product Name: RVU120
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2023
Details:
RVU120, a selective CDK8/CDK19 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors, is currently in phase I clinical development for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Lead Product(s): RVU120
Therapeutic Area: Oncology Product Name: RVU120
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BioNTech
Deal Size: $57.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 22, 2022
Details:
RVU120 (SEL120) is a small molecule selective CDK8 kinase inhibitor in clinical development for the treatment of acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as solid tumors.
Lead Product(s): RVU120
Therapeutic Area: Oncology Product Name: SEL120
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
Preclinical data demonstrate that treatment with RVU120, a small molecule inhibitor of CDK8/19 kinases, in combination with an anti-CD20 antibody causes upregulation of LAMP1 surface level and increases NK cell cytotoxicity against CD20-positive positive DLBCL cell lines.
Lead Product(s): RVU120
Therapeutic Area: Oncology Product Name: RVU120
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
Ryvu aims to address the clinical limitations of current treatments in oncology and provide patients with access to innovative therapies RVU120, for the treatment of haematologic and solid tumours.
Lead Product(s): RVU120
Therapeutic Area: Oncology Product Name: RVU120
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: European Investment Bank
Deal Size: $21.8 million Upfront Cash: Undisclosed
Deal Type: Financing August 17, 2022
Details:
RVU120 (SEL120) is a clinical-stage, highly specific, and orally bioavailable dual inhibitor of CDK8/CDK19 kinases, which has demonstrated efficacy in a number of solid tumor in vitro and in vivo models as well as in hematologic malignancies.
Lead Product(s): RVU120
Therapeutic Area: Oncology Product Name: SEL120
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
RVU120 (SEL120) is a highly selective first-in-class CDK8/CDK19 inhibitor, which has demonstrated efficacy in a number of solid tumor types in in vitro and in vivo models as well as in onco-hematological malignancies.
Lead Product(s): RVU120
Therapeutic Area: Oncology Product Name: RVU120
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Menarini
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
Details:
RVU120 (SEL120) is a highly selective first-in-class CDK8/CDK19 inhibitor, which has demonstrated efficacy in a number of solid tumor types in in vitro and in vivo models as well as in onco-hematological malignancies.
Lead Product(s): RVU120
Therapeutic Area: Oncology Product Name: RVU120
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2021
Details:
RVU120 (SEL120) is a selective CDK8/CDK19 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors.
Lead Product(s): RVU120
Therapeutic Area: Oncology Product Name: RVU120
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2021
Details:
This grant Supports Ryvu to develop and select a clinical candidate targeting cancers which had been considered in the past as largely undruggable using rational approaches.
Lead Product(s): RVU120
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Centre for Research and Development
Deal Size: $8.9 million Upfront Cash: Undisclosed
Deal Type: Agreement June 05, 2020
Details:
SEL120 has shown strong proof of concept in the preclinical studies and has received a strategic support from The Leukemia & Lymphoma Society (LLS) through its Therapy Acceleration Program.
Lead Product(s): RVU120
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
